Fortis Capital Management LLC Takes $120,000 Position in Altimmune, Inc. (NASDAQ:ALT)

Fortis Capital Management LLC purchased a new position in shares of Altimmune, Inc. (NASDAQ:ALT) in the 4th quarter, Holdings Channel.com reports. The firm purchased 16,606 shares of the company’s stock, valued at approximately $120,000.

Several other large investors have also recently made changes to their positions in the company. B. Riley Wealth Advisors Inc. increased its position in shares of Altimmune by 12.9% during the third quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock worth $144,000 after purchasing an additional 2,687 shares in the last quarter. Teacher Retirement System of Texas increased its position in shares of Altimmune by 19.2% during the fourth quarter. Teacher Retirement System of Texas now owns 21,205 shares of the company’s stock worth $153,000 after purchasing an additional 3,423 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Altimmune by 34.5% during the fourth quarter. Sequoia Financial Advisors LLC now owns 13,655 shares of the company’s stock worth $98,000 after purchasing an additional 3,500 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Altimmune by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares in the last quarter. Finally, Larson Financial Group LLC acquired a new position in Altimmune during the third quarter worth $31,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Stock Up 0.2 %

Shares of Altimmune stock opened at $5.79 on Friday. Altimmune, Inc. has a 52 week low of $5.14 and a 52 week high of $11.16. The business’s fifty day simple moving average is $6.33 and its 200-day simple moving average is $7.08. The firm has a market cap of $446.14 million, a PE ratio of -3.74 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. As a group, equities analysts expect that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ALT shares. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research note on Tuesday, March 18th. Finally, Stifel Nicolaus started coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $20.83.

Insider Activity

In other news, CFO Gregory L. Weaver acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The shares were purchased at an average price of $5.20 per share, for a total transaction of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $52,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.10% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.